1 |
Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behav Sci (Basel) 2021;11:74. [PMID: 34068064 DOI: 10.3390/bs11050074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Koziorowski D, Figura M, Milanowski ŁM, Szlufik S, Alster P, Madetko N, Friedman A. Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. Cells 2021;10:656. [PMID: 33809527 DOI: 10.3390/cells10030656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Caruso G, Torrisi SA, Mogavero MP, Currenti W, Castellano S, Godos J, Ferri R, Galvano F, Leggio GM, Grosso G, Caraci F. Polyphenols and neuroprotection: Therapeutic implications for cognitive decline. Pharmacol Ther 2021;:108013. [PMID: 34624428 DOI: 10.1016/j.pharmthera.2021.108013] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
4 |
Meneghini V, Peviani M, Luciani M, Zambonini G, Gritti A. Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System. Front Genome Ed 2021;3:644319. [PMID: 34713256 DOI: 10.3389/fgeed.2021.644319] [Reference Citation Analysis]
|